Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Psychiatric disorders – page 10

  • 546 clinical trials
  • 252 recruiting
  • 147 conditions
  • 26 countries

Conditions in this area

147 conditions with trials, the busiest first

Dementia Alzheimer's type87Major depression57Schizophrenia39Depression35Narcolepsy19Cognitive disorder18Bipolar disorder16Autism spectrum disorder15Insomnia15Post-traumatic stress disorder14Psychotic disorder14Drug use disorder13Alcohol use disorder12Attention deficit hyperactivity disorder9Dementia9Obstructive sleep apnoea syndrome9Brain injury8Irritable bowel syndrome8Phenylketonuria8Bipolar I disorder7Drug dependence7Hypersomnia7Lennox-Gastaut syndrome7Anorexia nervosa6+123

Clinical trials in Psychiatric disorders

546 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

546 clinical trials

Post-traumatic stress disorder

Recruiting

Title: Study of Hydrocortisone Treatment to Improve Fear Response in Adults with Post-Traumatic Stress Disorder (PTSD) and Hormonal System Changes

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Hydrocortisone
  • Sponsor:Stichting Radboud University Medical Center

Dementia Alzheimer's type

Recruiting

A study using [18F]RO6958948 PET imaging to examine brain tau protein deposits in people at risk of Alzheimer's Disease

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:2-(6-[18F]Fluoro-Pyridin-3-Yl)-9H-Dipyrido[2,3-B:3',4'-D]Pyrrole
  • Sponsor:Barcelonabeta Brain Research Center

Major depression

Recruiting

Study of milsaperidone as an additional treatment for adults with Major Depressive Disorder who are already taking antidepressants

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:(1S)-1-[4-[3-[4-(6-FLUORO-1,2-BENZOXAZOL-3-YL)PIPERIDIN-1-YL]PROPOXY]-3-METHOXYPHENYL]ETHANOL
  • Sponsor:Vanda Pharmaceuticals Netherlands B.V.

Premature ejaculation

Recruiting

Study on the Effectiveness of BP1.4979 for Adult Men with Premature Ejaculation

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:N-[4-[2-[4-(3-Cyanophenyl)Piperazin-1-Yl]Ethyl]Cyclohexyl]-3-Methoxypropanamide
  • Sponsor:Bioprojet Pharma

Dementia Alzheimer's type

Recruiting

Study on ITI-1284 for Treating Agitation in Alzheimer's Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Iti-1284
  • Sponsor:Intra-Cellular Therapies Inc.

Narcolepsy+1

Recruiting

Study on the Safety and Effects of ORX750 for Patients with Narcolepsy and Idiopathic Hypersomnia

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ORX750
  • Sponsor:Centessa Pharmaceuticals UK Limited

Psychotic disorder+2

Recruiting

Study on ITI-1284 for Treating Psychosis in Alzheimer's Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Iti-1284
  • Sponsor:Intra-Cellular Therapies Inc.

Insomnia+1

Recruiting

Study of Light Therapy and Melatonin for Treatment of Major Depressive Episode with Insomnia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Melatonin
  • Sponsor:Assistance Publique Hopitaux De Paris

Obesity+2

Recruiting

Study on the Effects of Semaglutide on Mood in Patients with Major Depressive Disorder and Overweight or Obesity

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Semaglutide
  • Sponsor:Region Hovedstaden

Hypersomnia

Recruiting

Study of TAK-360 tablets to evaluate safety and effectiveness in people with Idiopathic Hypersomnia

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Trisomy 21+1

Recruiting

Study of levetiracetam to prevent seizures in adults who have both Down syndrome and Alzheimer's disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Levetiracetam
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Narcolepsy+1

Recruiting

Long-Term Study on the Safety and Effects of ALKS 2680 for Patients with Narcolepsy Type 1 and Type 2

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alks 2680
  • Sponsor:Alkermes Inc.

Substances studied in this area

The therapies tested most often in Psychiatric disorders trials.

Sodium Chloride25 clinical trialsTrospium Chloride17 clinical trialsXanomeline Tartrate16 clinical trialsCannabidiol15 clinical trialsDry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol14 clinical trialsFlorquinitau (18F)14 clinical trialsOxytocin13 clinical trialsAripiprazole12 clinical trialsFlorbetaben (18F)12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.